Bet_Noire
The FDA has approved Novartis’ (NYSE:NVS) Cosentyx for the treatment of severe hidradenitis suppurativa, a debilitating skin disease, in adults.
Novartis said Cosentyx, also known as secukinumab, is currently the only IL-17A inhibitor approved for the condition.
Cosentyx is already approved in the US for the treatment of conditions such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondylarthritis.
Acelyrin (SLRN) and MoonLake Immunotherapeutics (MLTX) are also developing IL-17 inhibitor therapies for hidradenitis suppurativa.
(Adds Acelyrin and MoonLake to story.)